Daryl joined Neuren in May 2025. He brings almost 30 years of experience in the biopharmaceutical industry, most recently from the rare disease company Horizon Therapeutics, where he served as Sr. Vice President of Global Regulatory Affairs. Previous to Horizon Therapeutics, Daryl led Global Regulatory Affairs and Translation Sciences for Acadia Pharmaceuticals, where he was instrumental in the Phase 3 development and NDA supporting the FDA approval of trofinetide. Daryl also held regulatory affairs and product development leaderships roles at Shire, Sanofi and Searle-Pharmacia in multiple therapeutic areas, including CNS, and across drug, biologic and cell-therapy technologies. Earlier in his career, Daryl conducted clinical and nonclinical toxicology research for SmithKline Beecham Corporation and Parke-Davis and Company, respectively. Daryl earned his B.S. in Microbiology and Master in Public Health in Toxicology from the University of Michigan.